Epacadostat, Cladribine and Cytarabine (ECC) in AML
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
- Status
- COMPLETED
- Phase
- PHASE1
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
- Status
- WITHDRAWN
- Phase
- PHASE1
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT
- Status
- RECRUITING
- Phase
- PHASE2
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
- Status
- UNKNOWN
- Phase
- PHASE3
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
- Status
- UNKNOWN
- Phase
- PHASE3
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
- Status
- TERMINATED
- Phase
- PHASE2
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
- Status
- COMPLETED
- Phase
- PHASE3
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
- Status
- UNKNOWN
- Phase
- PHASE2
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
- Status
- COMPLETED
- Phase
- PHASE1
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE2